Analyst Michael Cherny of Leerink Partners maintained a Hold rating on DENTSPLY SIRONA (XRAY – Research Report), retaining the price target of $14.50.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Michael Cherny has given his Hold rating due to a combination of factors influencing DENTSPLY SIRONA’s current market position. The company showed a better-than-expected performance in the recent dental earnings season, with a slight decline in total company growth after adjusting for the Byte removal. This was coupled with improved cost management and margin enhancement, leading to an increase in the FY25 EBITDA margin guidance despite tariff considerations.
However, there are still several challenges that the company faces, with some areas showing gradual improvement while others remain stagnant. The analyst has increased the price target from $14.50 to $16.50, reflecting a cautious optimism based on the company’s EBITDA estimates for CY26. Despite these positive developments, the need for further progress in revitalizing key areas of the portfolio amid a volatile operating environment justifies maintaining the Hold rating.
Cherny covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, CVS Health, and Certara. According to TipRanks, Cherny has an average return of 3.2% and a 53.31% success rate on recommended stocks.
In another report released on May 9, J.P. Morgan also maintained a Hold rating on the stock with a $17.00 price target.